All News

lupus.GN_.jpg

Obintuzumab in Lupus Nephritis

EurekAlert

In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney con

Read Article
bone.infection.gram_.rod_.jpg

Incidence, Microbiological Studies, and Factors Associated With Prosthetic Joint Infection After Total Knee Arthroplasty

Jack Cush, MD

A study of nearly 80,000 US veterans who underwent primary knee joint arthroplasty (TKA) showed  the incidence of prosthetic joint infection (PJI) was highest in the first 3 months and remained elevated through 12 months compared with 12 months or more after surgery.

Read Article
genes_0.jpg

Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants

Jack Cush, MD

A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions.

Read Article
RheumNow Podcast square

Late Should Not Be Less (11.3.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.

Read Article
vaccination.jpg

H. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy

Jack Cush, MD

JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold.  Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV). 

Read Article
doctor.study_.decision_0.jpg

Oral Surveillance Study Alters Practice at VA

Jack Cush, MD

Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the Veterans Affairs (VA) health system, researchers found.

Read Article
Little disturbing to see the data that most patients using cannabis dont know what exact product they are using. Also not most is not prescribed/ illegal! Lots to learn and may have potential but need to be careful! @RheumNow #ACR23 https://t.co/Y0vHmVvWdL
Bella Mehta bella_mehta ( View Tweet)
Controlled substance rundown - CBD and THC are the key molecules Used since 5K years 18 percent of americans have used opiods once since 2019! @rheumnow #ACR23 https://t.co/iEscYxB5j5
Bella Mehta bella_mehta ( View Tweet)
FAST trial, MMF vs MTX at the Review Course today Overall a big win for MTX, powered for noninferiority (bc people loved MMF) but looks like MTX won the day w/10% difference in outcomes Take home: MTX FTW per usual @RheumNow #ACR23 #ReviewCourse https://t.co/lY1V6S7X3d
Mike Putman EBRheum ( View Tweet)
ACR convergence highlights by the awesome, i mean very awesome team @RheumNow Sunday to Thursday with recap Friday 🤓 i am stocking every one😂 https://t.co/WahAoH7MCM Biologic / target synthetic induced None melanoma skin cancer? Disease induced or medication induced ?

Nouf Al hemmadi  ( View Tweet)

I never tire of hearing this story. Biologic DMARDs revolutionized rheumatology & changed millions of lives. How did we get TNFi? Sharp translational insights & courage++ After 4w, RA gone, up/down stairs like a miracle. Sir Ravinder 'Tiny' Maini #ACR23 Global Summit @RheumNow https://t.co/Je1cz3cWG5
David Liew drdavidliew ( View Tweet)
Long term results of the MAINRITSAN study (Maintenance Remission w/ RTX in Systemic AAV) showed fixed-schedule RTX superior to AZA in preventing major relapses at 84mos (HR 0.38), but tailored-RTX assoc w/ incr risk of major relapse (HR 2.92) https://t.co/xLxvPCsRC9 https://t.co/mWwo7GgCIq

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologics, #RA and Risk of skin CA (NMSC) is complex. - RA alone is a risk for NMSC 49K study of ABA & NMSC ; - In RCTs, risk same w/ ABA & PBO - Registries & Claims data: equal w/ ABA, csDMARDs. b/tsDMARDs - Pooled obs data shows slight ABA risk https://t.co/tp6F0cJWug https://t.co/u6UdAUZqoc

Links:

Dr. John Cush RheumNow ( View Tweet)
Marijuana use is on the rise, including older adults. Data presented at 2023 AHA (cardiology) meeting suggests that marijuana user have higher risk of MI & CVA; & daily marijuana users were 34% more likely to develop heart failure (in hospitalized adults) https://t.co/EnEnf6pqdr https://t.co/GXSv30AFLr

Links:

Dr. John Cush RheumNow ( View Tweet)
New download available, titled "Dealing with Infections" https://t.co/hsOuJoFokg https://t.co/G3MZ9BQo0X

Links:

Dr. John Cush RheumNow ( View Tweet)
Oral Surveillance Study Alters Practice at VA Safety risks found in a postmarketing trial with the JAKi tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for RA patients in the VA health system, researchers found. https://t.co/6WktHCkrI1 https://t.co/8wpAeLsBbw

Links:

Dr. John Cush RheumNow ( View Tweet)
H. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV). https://t.co/QEPQJkfSjE https://t.co/pFk2mF22ex

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of German RABBIT registry did not show more MACE events in pts w/ JAK inhibitors compared to other DMARDs. 154 MACE w/ 14203 Rx episodes (21218 Pt-Yrs). IRs were 0.68 JAKi, 0.62 TNFi, 0.76 bdMARDs and 0.95 csDMARDs; higher in CV risk pts https://t.co/luUK9M9IM9 https://t.co/z8lxjWscCR

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiovascular and VTE Risk w/JAKi Treatment of Skin Disorders A JAMA systematic review and meta-analysis has shown the use of JAKi in immune-mediated inflammatory skin diseases was not associated w/ increased risk of all-cause mortality, MACE, or VTE. https://t.co/XYAeLnFvHr https://t.co/tGRNEUEZj9

Links:

Dr. John Cush RheumNow ( View Tweet)
Steroid (GC) use is increasing - Claims data from (US, Taiwan, Denmark; n=54,630,437; 2009-2018), GC use increased from 6.4 to 7.7% USA, 16.6 to 18.7% Taiwan, & 1.7 to 2.9% Denmark. Most Rx by PCP to healthy adults; 20-25% Rx for URI. https://t.co/GkQR0hcys1 https://t.co/5fpBv2Kyo8

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×